Brogden K A, Cutlip R C, Lehmkuhl H D
Infect Immun. 1986 Jun;52(3):644-9. doi: 10.1128/iai.52.3.644-649.1986.
Lipopolysaccharides (LPS) from Escherichia coli, Salmonella typhi, Klebsiella pneumoniae, Serratia marcescens, or Pseudomonas aeruginosa were mixed with pulmonary surfactant to investigate their in vitro interaction. After 6 h of incubation at 37 degrees C, LPS-surfactant mixtures were examined by sucrose density gradient centrifugation. The E. coli LPS-surfactant mixture was examined by immunoelectron microscopy with protein A-colloidal gold. The binding that occurred between LPS and the surfactant vesicles resulted in a complex with a density higher than the density of the surfactant alone. The protein A-colloidal gold identified LPS in the LPS-surfactant complexes. The toxicity of E. coli LPS was enhanced by complexing with the surfactant when compared with the intraperitoneal injection into CF1 mice, even at a 64:1 ratio of surfactant to LPS. The complexing of LPS and surfactant in the lung may alter the physiologic properties of surfactant that contribute to the physiopathological changes observed with some types of pneumonia.
将来自大肠杆菌、伤寒沙门氏菌、肺炎克雷伯菌、粘质沙雷氏菌或铜绿假单胞菌的脂多糖(LPS)与肺表面活性剂混合,以研究它们的体外相互作用。在37℃孵育6小时后,通过蔗糖密度梯度离心法检测LPS-表面活性剂混合物。用蛋白A-胶体金免疫电子显微镜检查大肠杆菌LPS-表面活性剂混合物。LPS与表面活性剂囊泡之间发生的结合导致形成一种密度高于单独表面活性剂密度的复合物。蛋白A-胶体金鉴定出LPS-表面活性剂复合物中的LPS。与向CF1小鼠腹腔注射相比,即使表面活性剂与LPS的比例为64:1,大肠杆菌LPS与表面活性剂复合后其毒性仍增强。LPS与表面活性剂在肺中的复合可能会改变表面活性剂的生理特性,而这些特性会导致在某些类型的肺炎中观察到的生理病理变化。